Pulmonary Fibrosis: When the Lung Turns to Scar
Most of this section has been about airways that narrow and open. Pulmonary fibrosis is a different kind of lung disease entirely — the lung tissue itself becomes stiff and scarred. For years nothing could touch it; now two drugs can at least slow it down. This closing article rounds out the specialised end of respiratory medicine.
Think about the difference between a disease of the airways and a disease of the lung tissue. Asthma and COPD are problems of the tubes — the airways narrow, and much of treatment is about opening them again. Pulmonary fibrosis is something else: here the delicate lung tissue where oxygen crosses into the blood becomes progressively thickened, stiff and scarred (fibrosis means scarring). A scarred lung can't stretch to breathe in properly and can't transfer oxygen well, so the person becomes increasingly breathless, especially on exertion, often with a persistent dry cough. The most important form, idiopathic pulmonary fibrosis, has no clear cause and steadily worsens. Because the problem is scarring rather than a reversible narrowing, the bronchodilators and steroids that dominate the rest of this section largely don't help — this disease needs a different approach.
Antifibrotic drugs — slowing the scarring
Two drugs can slow the decline, though not reverse it. For a long time, idiopathic pulmonary fibrosis had essentially no effective drug treatment — it was managed with oxygen and supportive care while the lungs slowly failed. The breakthrough came with two antifibrotic drugs: pirfenidone and nintedanib. Neither cures the disease or reverses the scarring already there, but both have been shown to slow the rate at which lung function declines — a meaningful benefit in a relentless disease, buying patients time and preserving function for longer. They work by interfering with the signalling processes that drive the scarring (nintedanib, for example, blocks growth-factor pathways involved in fibrosis). Their side effects are worth a brief note: both commonly cause gastrointestinal upset and can affect the liver (so liver monitoring is needed), and pirfenidone can cause marked skin sensitivity to sunlight. Beyond the drugs, care includes long-term oxygen as the disease advances, pulmonary rehabilitation, and — for suitable patients with severe disease — lung transplantation, which remains the only definitive treatment.
The respiratory section in one view
Pulmonary fibrosis is a fitting place to close, because it completes the map of lung disease. Step back and the whole respiratory section resolves into a few clear ideas. Most lung disease is about the AIRWAYS narrowing — and the two great tools are bronchodilators to open them (beta-2 agonists and antimuscarinics) and inhaled steroids to calm the inflammation, delivered by inhaler so they act locally with few side effects. Asthma is reversible and steroid-driven; COPD is largely fixed and bronchodilator-driven, with stopping smoking above all. Around this core sit the allergy drugs (antihistamines, and adrenaline for anaphylaxis), the acute-attack and oxygen emergencies, and the specialist diseases at the edges — cystic fibrosis, pulmonary hypertension and, here, fibrosis. Throughout, the same cross-cutting principles from earlier chapters kept reappearing: the autonomic receptors behind bronchodilators, the topical-steroid advantage, the blood-brain barrier behind antihistamine sedation, precision medicine in biologics and CFTR modulators, and even sildenafil turning up in the lungs. Learn respiratory pharmacology and you're not learning a list of drugs — you're seeing how a handful of deep ideas, met once, keep paying off across the whole of medicine.
- Pulmonary fibrosis = scarring/stiffening of the lung TISSUE itself (not narrowed airways).
- Bronchodilators and steroids largely don't help — it's scarring, not reversible narrowing.
- Antifibrotics (pirfenidone, nintedanib) SLOW the decline but don't reverse it.
- Side effects: GI upset and liver effects (monitor); pirfenidone → photosensitivity.
- Supportive care: long-term oxygen, rehabilitation; lung transplant is the only definitive option.
The airway-versus-tissue distinction is the perfect note to end on, because it explains why the section's flagship drugs suddenly stop working. Everything you learned for asthma and COPD — relievers, steroids, the whole reliever/controller framework — targets airways that are narrowed but structurally intact, and can be opened again. Pulmonary fibrosis breaks that assumption: the lung tissue itself is scarred, and you cannot open a scar with a bronchodilator any more than you can un-stiffen leather by pulling on it. That's why fibrosis needed an entirely new kind of drug, aimed not at relaxing muscle but at slowing the scarring process itself. It's a reminder to always ask what, structurally, has gone wrong — because the right drug depends not just on the symptom (breathlessness) but on the mechanism behind it.
- Expecting bronchodilators or steroids to help pulmonary fibrosis — the problem is scarring.
- Expecting antifibrotics to reverse fibrosis — they only slow the decline.
- Skipping liver monitoring on pirfenidone/nintedanib, or sun protection on pirfenidone.
- Assuming all breathlessness is airway disease — tissue diseases behave differently.
Why don't bronchodilators help pulmonary fibrosis?
- Pulmonary fibrosis is scarring of the lung tissue itself — not a reversible airway problem.
- Bronchodilators/steroids don't help; antifibrotics (pirfenidone, nintedanib) slow but don't reverse decline.
- Monitor liver; pirfenidone causes photosensitivity; oxygen and transplant for advanced disease.
- The section's map: airways (bronchodilators + inhaled steroids) at the core, specialist diseases at the edges.
- Katzung BG. Basic & Clinical Pharmacology — Drugs used in interstitial lung disease.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antifibrotic agents.
- ATS/ERS — Idiopathic pulmonary fibrosis: diagnosis & management guidelines.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — The respiratory system (fibrosis).
